ArticleArthritis research & therapy2021

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.

Emma Derrett-Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.